Carregant...
Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post–Liver Transplant Recurrent Hepatitis
Preliminary studies on HCV-cirrhotics listed for transplant suggest that Sofosbuvir in combination with Ribavirin is very effective in promoting viral clearance and preventing disease recurrence. Unfortunately, the high cost of such treatment (€46 500 per 12 weeks treatment) makes its cost-effective...
Guardat en:
| Publicat a: | Am J Transplant |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4946849/ https://ncbi.nlm.nih.gov/pubmed/26086300 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajt.13320 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|